Clinical trials: Cardiogenic Shock
Shock, Cardiogenic
A Study of the Safety and Efficacy of Nitric Oxide Reduction in Patients With Cardiogenic Shock After a Heart Attack
Tilarginine Acetate Injection is a new type of drug that temporarily stops the body from making a bodily substance called nitric oxide. The body may produce excess nitric oxide following severe heart damage leading to shock.
- Trial name
- NCT00112281
- Testing
- Tilarginine Acetate Injection intravenous infusion
- Where
- 102 sites in United States, Canada
- Volunteers
- 658 people
- Sponsor
- Arginox Pharmaceuticals
Cardiogenic Shock, Heart Failure
Magenta Elevate™ Clinical Feasibility Study in Cardiogenic Shock
The Elevate™ CS Clinical Feasibility Study is designed to evaluate the initial safety, effectiveness, and device performance of the Magenta Elevate™ System in patients with cardiogenic shock due to isolated or predominant left…
- Conditions
- Cardiogenic Shock, Heart Failure, Acute Myocardial Infarction (AMI)
- Trial name
- NCT07293923
- Testing
- Elevate™ System
- Where
- 8 sites in Georgia, Israel
- Volunteers
- 10 people
- Sponsor
- Magenta Medical Ltd.
Respiratory Failure, Respiratory Arrest
Postoperative Respiratory Abnormalities
The study aims to determine how historical cases of respiratory abnormalities are documented by clinicians in the electronic health records (EHR) of Memorial Hermann Healthcare System (MHHS) inpatient facilities.
- Conditions
- Respiratory Failure, Respiratory Arrest, Respiratory Distress Syndrome, Acute Respiratory Failure
- Trial name
- AI-ARF (NCT04079829)
- Testing
- Observational retrospective cohort to describe data validity; and Data reliability; and Completeness of the data
- Where
- United States
- Volunteers
- 50,000 people, healthy volunteers welcome
- Sponsor
- Efficacy Care R&D Ltd
Cardiogenic Shock, Extracorporeal Membrane Oxygenation Complication
Comparison of Four Intensive Care Scores in Prediction of VA-ECMO Survival.
VA-ECMO is increasingly utilized in the setting of cardiogenic shock or cardiac arrest to restore hemodynamic stability and end organ function.
- Trial name
- ECMO (NCT05730881)
- Testing
- ECMO
- Where
- Qatar
- Volunteers
- 200 people
- Sponsor
- Hamad Medical Corporation
Right Heart Catheterization
The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases.
- Trial name
- NCT05629533
- Testing
- SimpleSense
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nanowear Inc.
Cardiogenic Shock
Thoratec Corporation HeartMate PHP™ Cardiogenic Shock Trial
The primary objective of this study is to assess reasonable safety and performance of the HeartMate PHP to provide hemodynamic support for up to 72 hours in patients with cardiogenic shock requiring stabilization.
- Trial name
- NCT02279979
- Testing
- HeartMate PHP
- Where
- 6 sites in Czechia, Germany and 2 more
- Volunteers
- 9 people
- Sponsor
- Abbott Medical Devices
AMI Cardiogenic Shock
Assessment of Support With Impella® Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
The observational study titled "Observational Assessment of Support with Impella Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock (OASIS-AMICS)" aims to evaluate the safety outcomes of patients with…
- Trial name
- OASIS-AMICS (NCT06964685)
- Testing
- Impella
- Where
- 21 sites in United States
- Volunteers
- 350 people
- Sponsor
- Abiomed Inc.
Cardiogenic Shock
Efficacy and Safety of the CorVad Percutaneous Ventricular Assist System in Cardiogenic Shock
This study aims to evaluate the safety and effectiveness of the CorVad Percutaneous Ventricular Assist System for providing circulatory support in patients with cardiogenic shock caused by cardiomyopathy.
- Trial name
- NCT06646224
- Testing
- CorVad Percutaneous Ventricular Assist System
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shenzhen Core Medical Technology CO.,LTD.
Shock, Cardiogenic
A Phase 1b/2a Trial to Evaluate Invobenitug Also Known as Procizumab (PCZ; AK1967) in Critical Cardiovascular Care.
The objective of this Phase 1b/2a trial is to evaluate the safety, tolerability, and exploratory efficacy of invobenitug (also known as procizumab), a monoclonal antibody under development for the treatment of cardiogenic shock…
- Trial name
- PROCARD 2a (NCT06832722)
- Testing
- AK1967 (Invobenitug also known as Procizumab)
- Where
- 37 sites in Armenia, Belgium and 7 more
- Volunteers
- 90 people
- Sponsor
- 4TEEN4 Pharmaceuticals GmbH